Accufix Surgical has reported that 200 procedures have been completed using its Accu-Joint Hemi implant, a solution to address the limitations of traditional joint implants and fusion surgery.

The company said this milestone validates its approach to MTP joint treatment, which concentrates on bone preservation and natural motion while avoiding complications related to prior implant designs. The U.S. Food and Drug Administration (FDA)-approved Accu-Joint Hemi provides new options for patients seeking fusion alternatives in the foot and ankle.

The implant system has patented instrumentation that allows bone resurfacing without significant resection. It requires 1 mm of bone removal, according to Accufix.

The bone-preserving approach and non-weight bearing design can allow quicker recovery and maintain natural joint biomechanics.

“Reaching 200 successful procedures demonstrates the growing adoption of our innovative approach to MTP joint disorders,” said John Evans, CEO of Accufix Surgical. “Our mission has always been to provide surgeons and patients with better alternatives to fusion. The Accu-Joint’s bone-preserving design and non-weight bearing mechanics are transforming how we think about joint preservation, and these 200 cases validate our technology’s potential to improve patient outcomes.”

“The feedback from both surgeons and patients has been overwhelmingly positive,” Evans went on. “We’re seeing patients return to their active lifestyles more quickly, with many able to bear weight on their toe from day one. This milestone isn’t just about numbers—it’s about 200 individuals who have maintained their mobility and quality of life.”